About: Advax Delta Inulin Adjuvant Overcomes Immune Immaturity In Neonatal Mice Thereby Allowing Single

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Advax Delta Inulin Adjuvant Overcomes Immune Immaturity In Neonatal Mice Thereby Allowing Single–Dose Influenza Vaccine Protection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Advax Delta Inulin Adjuvant Overcomes Immune Immaturity In Neonatal Mice Thereby Allowing Single–Dose Influenza Vaccine Protection
Creator	Honda-Okubo, Yoshikazu Petrovsky, Nikolai Hao Ong, Chun
source	Elsevier; Medline; PMC
abstract	Neonates are at high risk for influenza morbidity and mortality due to immune immaturity and lack of priming by prior exposure. Inactivated influenza vaccines are ineffective in infants under six months and to provide protection in older children generally require two doses given a month apart. This leaves few options for rapid protection of infants, e.g. during an influenza pandemic. We investigated whether Advax™, a novel polysaccharide adjuvant based on delta inulin microparticles could help overcome neonatal immune hypo-responsiveness and also whether it was possible to obtain single-dose influenza vaccine protection of babies against lethal infection. Inactivated influenza A/H1N1 vaccine (iH1N1) combined with Advax™ adjuvant administered as a single immunization to 7-day-old mouse pups significantly enhanced serum influenza-specific IgM, IgG1, IgG2a and IgG2b levels in association with a 3–4 fold increase in the frequency of splenic influenza-specific IgM and IgG antibody secreting cells versus pups immunized with iH1N1 alone. Pups immunized with Advax-adjuvanted iH1N1 had significantly higher influenza-stimulated splenocyte production of IFN-γ, IL-2, IL-4, and IL-10 and a 3–10 fold higher frequency of T cells IFN-γ secreting IL-2, IL-4 or IL-17 by ELISPOT. Immunisation with iH1N1+Advax adjuvant induced robust protection against influenza virus challenge 3 weeks post-immunization, whereas pups immunized with iH1N1 alone had no protection. Protection by Advax-adjuvanted iH1N1 was mediated by serum antibody and memory B cells rather than memory T cells as protection was lost in neonatal µMT mice that are B-cell deficient. Hence, Advax adjuvant overcame neonatal immune hypo-responsiveness and enabled single-dose protection of pups against otherwise lethal influenza infection, thereby supporting development of Advax™ as a neonatal vaccine adjuvant.
has issue date	2015-09-01(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2015.07.051
bibo:pmid	26232344
has license	green-oa
sha1sum (hex)	96087de237f212abb07044bfee6b357c7376083c
schema:url	https://doi.org/10.1016/j.vaccine.2015.07.051
resource representing a document's title	Advax Delta Inulin Adjuvant Overcomes Immune Immaturity In Neonatal Mice Thereby Allowing Single–Dose Influenza Vaccine Protection
has PubMed Central identifier	PMC4562881
has PubMed identifier	26232344
schema:publication	Vaccine
resource representing a document's body	covid:96087de237f212abb07044bfee6b357c7376083c#body_text
is schema:about of	named entity 'SINGLE' named entity 'fold' named entity 'antigen' named entity 'neonatal' named entity 'morbidity' named entity 'adjuvant' named entity 'combined' named entity 'influenza' named entity 'neonatal' named entity 'Protection' named entity 'induced' named entity 'adjuvant' named entity 'immune' named entity 'robust' named entity 'subcutaneous' named entity 'influenza A/H1N1' named entity 'adjuvant' named entity 'IGG ANTIBODY' named entity 'HELP' named entity 'VACCINE' named entity 'ASSOCIATED WITH' named entity 'SUPPORTING' named entity 'MORBIDITY AND MORTALITY' named entity 'INDUCED' named entity 'TESTED' named entity 'SPECIFIC' named entity 'POLYSACCHARIDE' named entity '3-4' named entity 'POSSIBLE' named entity 'MEMORY B CELLS' named entity 'ONGOING' named entity 'DOSES' named entity 'IGG1' named entity 'DUE TO' named entity 'IL-10 PRODUCTION' named entity 'ADJUVANT' named entity 'IMMUNE' named entity 'INFLUENZA A' named entity 'CHILDREN' named entity 'EXPOSURE' named entity 'MONTH' named entity 'INEFFECTIVE' named entity 'RATHER' named entity 'SPLENIC' named entity 'IMMATURITY' named entity 'OVERCOME' named entity 'DOSE' named entity 'IGG2A' named entity 'DAY-OLD' named entity 'PRIMING' named entity 'ANTIGEN' named entity 'MOUSE' named entity '90%' named entity 'PROTECTION' named entity 'IMMUNE' named entity 'CBA' named entity 'IGG2B' named entity 'LEAVES' named entity 'IMMUNIZED' named entity 'CHALLENGE' named entity 'OBTAIN' named entity 'INFLUENZA VACCINES' named entity 'COMBINED' named entity 'DEVELOPMENT' named entity 'OPTIONS' named entity 'IL-2' named entity 'HIGH RISK' named entity 'T CELLS' named entity 'INULIN' named entity 'DELTA' named entity 'INFLUENZA VACCINE' named entity 'SERUM' named entity 'INULIN' named entity 'LEVELS' named entity 'IMMUNIZATION' named entity 'INFANTS' named entity 'ADMINISTERED' named entity 'RAPID' named entity 'B-CELL'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software